HIV and ID Observations

December 8th, 2009

Vancouver, Phishing Phlu Scam, Telavancin, and Cartoon

A few things to ponder as the flu activity (mercifully) declines, at least for now: Interested in evidence that HIV treatment has become staggeringly effective?  Fully 87% of patients receiving treatment in the large British Columbia cohort have an HIV RNA < 50; not only that, the incidence of HIV drug resistance has declined more than […]

---

December 2nd, 2009

So Much in Less than a Week!

First the updated WHO Guidelines.  Then the following: Updated DHHS Guidelines.  Agree?  Disagree?  Sensible or crazy?  Practical or ivory-tower academic? South Africa does the right thing.  Yes, it’s about time, but good news nonetheless. 2012 International AIDS Meeting in Washington, D.C. First time in USA in a long, long time — 1990, to be exact — […]

---

November 30th, 2009

WHO HIV Treatment Guidelines Updated

This just in: WHO is now recommending that ART be initiated at a higher CD4 threshold of 350 cells/mm3 for all HIV-positive patients, including pregnant women, regardless of symptoms. Which makes eminent sense, of course.  Because if starting HIV therapy might prolong survival in developed countries, why shouldn’t it do the same in the developing world? In fact, […]

---

October 31st, 2009

Would Changing Restrictive HIV Testing Laws Improve Survival?

Emphatically yes — to the tune of >600,000* years of life gained nationwide.  So says a nifty paper being presented at the annual IDSA meeting today by Mike April, under the direction of Rochelle Walensky. (*Original abstract said 549,437, cited in the link; number at the actual presentation, though, was 609,656.) Bottom line is that laws that […]

---

October 20th, 2009

Well That Was Fast! HIV Vaccine Trial Published

Remember the HIV vaccine trial press release?  The one announcing the first-ever positive result? Then the backlash, with people questioning how the analyses were done, and reported? Now, less than a month later, we have the scientific presentation and the paper appear on the same day. Read all about it here and here. If you want the view […]

---

October 12th, 2009

AIDS Vaccine: Maybe not Effective After All

Well, that didn’t take long: Researchers from the U.S. Army and Thailand announced last month they had found the first vaccine that provided some protection against HIV. But a second analysis of the $105 million study, not disclosed publicly, suggests the results may have been a fluke, according to AIDS scientists who have seen it. In short, […]

---

September 18th, 2009

Integrase Inhibitors: In Search of an Abbreviation

The alphabet soup that characterizes HIV therapeutics has always been one of its quirky challenges — for example, who could possibly know that 3TC, CBV, TZV, EPZ, and LAM all refer to drugs that are (or contain) lamivudine? This drives our ID fellows nuts, and is certainly a strong deterrent to non-HIV specialists to learning the field. […]

---

September 16th, 2009

News Flash: The Internet Cannot Replace an Actual Human

Interested in researching the cause of AIDS?  Well go ahead and give NetBase Solutions’ healthBase a try, but don’t expect much in the way of filtering: One of the most unfortunate examples is when you type in a search for “AIDS,” one of the listed causes of the disease is “Jew.” Really. The ridiculousness continues. […]

---

September 12th, 2009

49th ICAAC Starts Today

Browsing through the program book, I see these topics extensively covered: H1N1 and seasonal flu, in all their glory — transmission, pathogenesis, treatment, predictions Highly resistant GNR — acinetobacter, carbapenemases, ESBL, etc. MRSA — my personal favorite C diff — though perhaps a little less this year? While no one expects ICAAC to be an HIV-focused […]

---

September 2nd, 2009

Etravirine Warning

From the FDA Advisory: There have been postmarketing reports of cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme, as well as hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure. Intelence therapy should be immediately discontinued when signs and symptoms of severe skin or hypersensitivity reactions develop. These rare — […]

---